Myelodysplastic syndrome (MDS) can be broadly described as malignant stem-cell disorders that are generally detected among elderly patients with anemia. About 25% of all patients with MDS develop acute leukaemia. Although the median survival time for patients is around 30 months from the time of diagnosis, the disease course varies from patient to patient.
Therefore, it is very important to estimate the prognosis of the MDS as accurately as possible. In this video, Dr. Suvir Singh discusses myelodysplastic syndrome and the warning symptoms of myelodysplastic syndrome in a patient having unexplained anemia .
